Cellzome GmbH

Cellzome is a leader in Chemoproteomics, a technology which monitors the interaction of small molecules with their protein targets under close-to-physiological conditions, directly in cells or tis-sues.Cellzome was founded 2000 as a spin-off of the European Molecular Biology Laboratories (EMBL) and is located on the EMBL campus in Heidelberg, Germany. About 55 scientists and technical staff working at Cellzome represent 10 different nationalities and cover a variety of skill sets, ranging from physics, mass spectrometry and bioinformatics to cell biology, compound screening, and me-dicinal chemistry. As an independent company, Cellzome entered two drug discovery collaborations with the GlaxoSmithKline (GSK) Immuno-Inflammation therapy area, the first, initiated September 2008, focused on kinases and the second, initiated 2010, on epigenetic targets. The company was acquired by GSK in May 2012 and was integrated as fully owned GSK daughter company in GSK’s Platform Technology and Sciences team.Cellzome’s technology
Cellzome has pioneered the advancement of chemoproteomics to study the effects of active small molecules on the proteome, the protein content of a cell or tissue, which comprises in excess of 10,000 different proteins. We apply chemoproteomics in a quantitative manner at various stages in drug discovery and development, from screening to selectivity profiling of drugs in different cell and tissue types. A complementary platform is used to map disease-relevant signaling pathways. This is achieved by the quantitative characterization of multi-protein complexes or mapping of post-translational modifications, and the effect of drug candidates on these systems when applied in vitro or in vivo. Cellzome has published 10 landmark articles in the Nature journals which describe these approaches.